A newly developed dual-action drug, Ivonescimab, has shown promise in extending the lives of patients with advanced squamous non-small cell lung cancer when combined with chemotherapy, according to results from a clinical trial.
How the Drug Works
The investigational treatment operates through a dual mechanism. It disables the 'off' switch that tumours use to evade the immune system and simultaneously targets a protein crucial for tumour growth. This two-pronged approach aims to enhance the body's natural defences while directly inhibiting cancer progression.
Trial Results
A trial involving 532 patients in China found that those receiving Ivonescimab alongside chemotherapy lived an average of 28 months, representing a 15 per cent increase compared to a control group receiving standard treatment. Experts have described these findings as a “promising step forward” for this hard-to-treat form of lung cancer, though further investigation is required to confirm the results in broader populations.
Side Effects
While side effects were more common with the new drug combination, the rate of patients discontinuing treatment due to adverse effects remained similar across both treatment groups. This suggests that the added side effects were manageable for most patients.
Ivonescimab is still in the investigational stage, and additional studies are needed to evaluate its long-term efficacy and safety. However, these initial results offer hope for patients with advanced squamous non-small cell lung cancer, a subtype that has historically been difficult to treat.
